Background. β-lactam allergy skin testing (BLAST) is recommended by antimicrobial stewardship program (ASP) guidelines, yet few studies have systematically evaluated its impact when delivered at point of care.
Reported allergy to β-lactams is detrimental to patients with infectious diseases. Prior observational studies have suggested worse clinical outcomes among those with a β-lactam allergy label, including increased in-hospital mortality [1] and prolonged length of stay [1, 2] . These patients frequently receive less effective second-line therapies due to their reported allergy [3] [4] [5] and broader-spectrum antimicrobial agents that contribute to the development and spread of antimicrobial resistance [2] . A recent prospective cohort study of patients with reported β-lactam allergy identified detrimental clinical outcomes among those receiving alternative second-line agents, including adverse drug reactions and readmission to hospital for the same infection [6] . Conversely, those who received β-lactam therapy despite their reported allergy were at no higher risk of adverse events than patients without this allergy label [6] .
As most patients with a reported β-lactam allergy could safely tolerate β-lactams, promoting their use when clinically indicated is increasingly regarded as a function of antimicrobial stewardship [7] [8] [9] . The Infectious Diseases Society of America/ Society for Healthcare Epidemiology of America 2016 guidelines for the implementation of antimicrobial stewardship programs (ASPs) recommend that these patients undergo allergy assessment and β-lactam allergy skin testing (BLAST) when appropriate [10] . This simple, inexpensive, and reliable test carries high negative predictive value (97%-99%) for excluding the presence of immediate-type hypersensitivity [11, 12] ; however, it is not routinely available to institutions that lack expertise in allergy and immunology. In addition, the quality of evidence to support the use of BLAST by ASPs remains weak, with few studies that have systematically evaluated its impact on antimicrobial use and clinical outcomes among hospitalized patients [12] [13] [14] .
We conducted a prospective multicenter study with 3 objectives: (1) to determine the feasibility of implementing pointof-care BLAST as a pharmacist-led antimicrobial stewardship activity; (2) to evaluate the impact of BLAST on the use of preferred β-lactam therapy for management of patients with infectious diseases; and (3) to determine whether point-of-care BLAST is associated with improved infection-related clinical outcomes.
METHODS

Study Design
We performed a multicenter, prospective pragmatic evaluation of point-of-care BLAST at 3 participating hospitals in Toronto, Canada: Sunnybrook Health Sciences Centre (SHSC), an academic teaching hospital with 627 acute care beds; Michael Garron Hospital (MGH), a 339-bed community hospital; and North York General Hospital (NYGH), a community hospital with 427 acute care beds. Each hospital site has an infectious diseases (ID) consult service and an established ASP that includes 2 full-time pharmacists who perform audit and feedback of all hospitalized patients receiving targeted antimicrobial therapy (third-generation cephalosporins, piperacillin-tazobactam, carbapenems, vancomycin, fluoroquinolones, aminoglycosides) in collaboration with the ID physician on call.
All sites began baseline data collection 6 July 2015. The intervention was deployed in staggered 3-month intervals beginning with SHSC (5 October 2015), then MGH (4 January 2016), and finally NYGH (4 April 2016). The intervention period continued until study completion on 30 September 2016. The study was approved by the research ethics board at each hospital.
Training, Roles, and Responsibilities
All pharmacists (2 at each site) and a minimum of one ID physician at each hospital completed dedicated training prior to offering BLAST in their ASP. Training included completion of certification in standard first aid and cardiopulmonary resuscitation, an injection training course as per the Ontario College of Pharmacists [15] (pharmacists only), a half-day observation in the Drug Safety Clinic at SHSC, and a half-day hands-on training session by a drug safety clinic allergist on how to perform and interpret BLAST.
Informed consent was always the responsibility of the ID physician, and the prick testing and intradermal injections were performed by trained pharmacists as a delegated act [16, 17] , authorized by the ID physician. The β-lactam challenge was ordered by the ID physician and administered by the patient's nurse. The ID physician was available in hospital on page throughout the entire procedure.
Patient Population and Eligibility for β-lactam Allergy Skin Testing
Patients with reported β-lactam allergy were identified by the ASP through audit and feedback and the ID consultation service. As part of routine clinical activities, allergy history is obtained and patients with reported β-lactam allergy are prescribed preferred antimicrobial therapy, including β-lactam therapy whenever the benefit is deemed to outweigh any risks. These clinical assessments occurred in the same fashion during the intervention period with the only difference being that the ASP could offer BLAST whenever the severity of the patient's reported allergy prevented the ASP/ID service from prescribing the preferred β-lactam therapy (eg, vancomycin is prescribed for methicillin-susceptible Staphylococcus aureus instead of cefazolin due to history of anaphylaxis to penicillin). Exclusion criteria for BLAST included history suggestive of prior severe non-immunoglobulin E (IgE) reactions (eg, history of blistering rash, fever, mucous membrane involvement, joint involvement, cytopenia, renal failure), documented IgE reaction within the past 3 months, anticipated discharge within 24 hours of assessment, or declining consent to undergo BLAST.
Performing β-lactam Allergy Skin Testing
BLAST was offered on Mondays to Fridays throughout the study. When a patient with reported β-lactam allergy was confirmed to be eligible for BLAST based on the initial assessment by the ASP/ID service, informed consent was obtained and documented in the patient's medical chart by the ID physician. A medication review was performed by the ASP pharmacist to identify and hold any medications with antihistaminic properties, when possible (see Supplementary Appendix A for details). BLAST was generally performed the morning after the patient's initial assessment but deferred for 1-3 days in patients assessed on a Friday, or when there was a need to hold medications with antihistaminic properties for >1 day.
Trained ASP pharmacists performed prick testing and intradermal injections, which were read at 15 and 30 minutes, respectively. All negative BLASTs were followed by a β-lactam challenge followed by a 4-hour observation period by the patient's nurse. Full details regarding allergy testing protocol are available in Supplementary Appendix B. All patients with negative intradermal testing and β-lactam challenge were immediately switched to preferred β-lactam therapy. Their allergy label in the hospital electronic medical record was updated with the date and results of the negative allergy testing. Additionally, all patients were provided a letter explaining the significance of the negative test for being able to receive β-lactam antibiotics in the future, and were encouraged to share this letter with their outpatient pharmacy and community healthcare providers (eg, outpatient pharmacist, family doctor, dentist).
Data Collection
All inpatients reviewed by the ASP through audit and feedback and the ID consultation service with a reported β-lactam allergy were included in the study. De-identified data were prospectively recorded into an electronic data capture system including patient characteristics such as age, gender, comorbidities, and length of hospital stay at time of assessment. Allergy history was prospectively collected and classified into one of the following categories: simple rash, intolerance (nonallergic), unknown, severe IgE-mediated (including urticaria or hives, angioedema, or anaphylaxis), or severe non-IgE mediated (including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms or serum sickness). Only the antimicrobial therapy received following the initial assessment by ASP/ID service was recorded. Whether preferred therapy was a β-lactam was determined based on the initial assessment by the ID physician. When preferred therapy was a β-lactam, any patient who received a non-β-lactam or a β-lactam that was broader in spectrum than the preferred therapy (eg, meropenem instead of piperacillin-tazobactam) was considered to be receiving nonpreferred therapy. Each site allocated the specific patient's therapy as preferred or nonpreferred based on their own assessment. For simplicity of analysis, group assignment (either preferred or nonpreferred therapy) as determined based on this initial assessment did not change even if new clinical information or culture results became available later. Development of any adverse reaction to antibiotic therapy was recorded for all patients in the study, regardless of whether or not they received preferred β-lactam therapy.
Following study completion, clinical outcomes were abstracted retrospectively including discharge date, readmission to hospital, reason for readmission, and any delayed complications of antimicrobial therapy. The independent abstractor was blinded to whether or not patients received preferred therapy or underwent BLAST, and the study period (baseline vs intervention).
Study Outcomes and Statistical Analysis
Descriptive statistics were calculated for all variables of interest. Continuous measures were summarized using means and standard deviations whereas categorical measures were summarized using counts and percentages.
The primary outcome was the proportion of patients receiving preferred β-lactam therapy during the intervention periods compared to baseline. This analysis was carried out using a generalized estimating equation (GEE) model with a logit link function, adjusting for the correlation among observations at the same hospital and the time period, as well as the following patient-level variables: comorbidity index, admission to critical care unit, and presence of a positive blood or sterile site culture.
Secondary outcomes were development of any adverse drug reaction related to antibiotic therapy received, length of hospital stay from the time of assessment (analyzed using a linear model adjusting for correlation among hospitals), and a composite of 30-day infection-related readmission or death (also analyzed using a GEE model). All analyses were carried out using SAS version 9.4 software (SAS Institute, Cary, North Carolina).
RESULTS
In total, 827 patients reviewed by the ASP/ID service throughout the study reported a β-lactam allergy, including 632 (76%) in whom β-lactam therapy was preferred and 195 (24%) in whom no antibiotics were indicated or non-β-lactam was preferred. The specific reported β-lactam allergy was a penicillin in 557 (88%), a cephalosporin in 43 (7%), and both in 32 (5%) of cases. The patient characteristics of those in whom β-lactam therapy was preferred are displayed in Table 1 . There was older age among patients during the baseline period (P = .01) and a higher proportion with positive blood cultures during the intervention periods (P = .01); otherwise, the groups were similar with notably no significant difference in the proportion of patients with history of severe IgE-mediated reactions (P = .2).
Among 386 patients during the intervention period, 232 (60%) received preferred β-lactam therapy following ASP/ID assessment during the intervention period while 154 (40%) were eligible for BLAST (Table 2 ). Among these, 64 (42%) were excluded: 5 (8%) with history of severe non-IgE-mediated reactions, 14 (22%) with documented IgE-mediated reaction within the prior 3 months, 22 (34%) who were being discharged within 24 hours of assessment, 13 (20%) who refused to consent, and 10 (16%) whose nonpreferred therapy became the preferred treatment for management of their infection based on follow-up clinical or microbiologic information. The remaining 90 (58%) eligible patients underwent BLAST, of whom 85 (94%) were negative, 4 (4%) were nondiagnostic (histamine prick test negative), and 1 (1%) was positive. All 85 patients with negative BLAST tolerated the β-lactam challenge and 84 were switched to preferred β-lactam therapy, of whom 1 (1%) developed a nonsevere rash 1 day later requiring discontinuation and 83 (99%) tolerated β-lactam course without any immediate complications. Table 2 displays the study outcomes at all 3 hospitals. A significant increase in the use of preferred β-lactam therapy was noted at each hospital during the intervention period, compared to baseline. Overall, 50% (124/246) received preferred β-lactam therapy at baseline, compared with 60% (232/386) during the intervention periods based on history alone (P = .02), which improved further to 81% (313/386) upon provision of BLAST (P < .001). The proportion of days of penicillin nearly tripled (11% vs 32%; P < .0002), whereas carbapenem and fluoroquinolone use decreased by more than half (28% vs 13%; P < .0002).
Receipt of preferred β-lactam therapy was increased among patients admitted to the critical care unit (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .02) and with high comorbidity index (OR, 1.2; 95% CI, 1.0-1.4; P = .06), whereas culture positivity was not statistically significant (P = .4). After (14) 9 (4) 7 (3) 15 (14) 7 (11) 40 (16) 45 (12) Heart failure 6 (9) 27 (12) 6 (3) 5 (2) 18 (16) 8 (12) 30 (12) 40 (10) Prior myocardial infarction 10 (15) 33 (15) 10 (4) 4 (2) 7 (6) 8 (12) 27 (11) 45 (12) COPD 7 (10) 13 (6) 15 (7) 25 (11) 20 (18) 12 (18) 42 (17) 50 (13) Diabetes mellitus 10 (15) 62 (27) 16 (22) 15 (21) 37 (34) 13 (20) 63 (26) 90 (23) Peripheral vascular disease 3 (4) 14 (6) 8 (4) 5 (2) 3 (3) 1 (2) 14 (6) 20 (5) Liver disease 0 4 (2) 3 (4) 6 (6) 0 0 3 (1) 10 (3) Chronic kidney disease 6 (9) 27 (12) 4 (2) 10 (4) 14 (13) 9 (14) 24 (10) 46 (12) Cancer 17 (26) 48 (21) 10 (13) 10 (4) 16 (15) 17 (26) 43 (17) 74 (20) Connective tissue disease 2 (3) 4 (2) 0 0 10 (9) 1 (2) 12 (5) 5 (1) Charlson comorbidity index, median (IQR) (10) 8 (11) 12 (12) 20 (18) 16 (24) 36 (15) 51 ( Positive blood culture 11 (17) 49 (22) 7 (10) 17 (18) 12 (11) 11 (17) 30 (12) 77 (20) Other sterile site positive 11 (17) 27 (12) 1 (1) 4 (4) 4 (4) 4 (6) 17 (7) 35 (9) Reported (11) 4 (5) 7 (7) 10 (9) 4 (6) 16 (7) 36 (9) Angioedema 1 (2) 16 (7) 3 (4) 4 (4) 0 4 (6) 4 (2) 24 (6) Anaphylaxis 12 (18) 20 (9) 15 (21) 18 (19) 8 (7) 4 (6) 35 (14) 42 (11) Intolerance (nonallergic) 5 (8) 8 (4) 5 (7) 1 (1) 4 (4) 8 (12) 14 (6) adjusting for these variables and the correlation between hospitals, the intervention period was associated with a 4.5-fold greater odds of receiving preferred β-lactam therapy (95% CI, 2.4-8.2; P < .0001). Table 3 depicts the patients who received preferred β-lactam therapy during baseline and intervention periods based on severity of their reported IgE-mediated allergy. Among those with reported severe IgE-mediated reaction, there was no significant difference in the receipt of preferred β-lactam therapy during the intervention period following initial ASP/ID service assessment but, following BLAST, a significant increase was noted (P < .01). With respect to secondary clinical outcomes, there was no significant difference in infection/treatment-related 30-day readmission or death, or hospital length of stay at any of the hospitals and no difference overall before or after adjusting for predictor variables (data not shown). Despite the increase in preferred β-lactam therapy, there was no change in the incidence of adverse drug reactions during the intervention period (3% vs 4%; P = .4).
DISCUSSION
In this pragmatic multicenter prospective evaluation, ASP pharmacist-physician teams were trained by allergists at 3 hospitals to perform BLAST at the point of care to optimize the management of patients with infectious diseases who were receiving nonpreferred therapy due to severity of their reported β-lactam allergy. Receipt of preferred β-lactam 
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therapy increased significantly at all 3 hospitals following availability of BLAST, without any significant increase in antibiotic-related adverse drug reactions.
Safely preserving the use of β-lactam therapy among patients with reported allergy is the mandate of ASPs, and begins with collecting an appropriately detailed history to confirm that β-lactam therapy can be safely administered despite the patient's allergy label [10] . A prior quasi-experimental evaluation of a clinical algorithm to assessing β-lactam allergies resulted in a significant decrease in alternative second-line agents without any increase in adverse events [18] . Similarly, we noted improved use of preferred β-lactam therapy following clinical assessments during the intervention period, likely due to a more systematic approach to allergy history assessment in determining whether patients were eligible for BLAST.
Despite this, between 20% and 30% of patients reporting β-lactam allergy have a history of severe IgE-mediated reactions, which requires formal allergy testing to exclude persistent hypersensitivity before being able to safely prescribe β-lactam therapy [18] . This clinical reality is reflected in our data, which showed that receipt of preferred β-lactam therapy among this subgroup of patients remained unchanged during the intervention period based on history alone, and only increased significantly with provision of BLAST (Table 3) . This simple bedside test provided the necessary reassurance for both patients and clinical teams to administer the preferred β-lactam therapy despite a history of prior severe IgEmediated reaction.
While ASPs are mandated across hospitals, many institutions lack access to expertise in allergy including BLAST. Our study suggests that BLAST is a feasible ASP activity as it was successfully implemented across both academic and community hospital settings. With appropriate training, we believe that the combined pharmacist-physician model for performing BLAST among patients with documented infectious diseases has several advantages. Pharmacists already play a central role in ASPs, and BLAST is an opportunity to expand this role [10] . Once trained to perform BLAST, this skill can be maintained even when different physicians and trainees rotate on the clinical service. In addition, pharmacists are ideally suited to identify and prepare patients for BLAST, including clarification of the allergy history and medication review to identify those with antihistamine properties that should be held prior to performing BLAST.
Introduction of BLAST was associated with improved use of β-lactam therapy at all 3 hospitals compared to baseline. The use of penicillin nearly tripled while alternative agents associated with greater risk of Clostridium difficile infection, such as fluoroquinolones and carbapenems, decreased by more than half. Interestingly, the use of vancomycin remained unchanged throughout the study, which may be related to its ongoing use as combination therapy among patients who also received preferred β-lactam therapy. The improved antibiotic prescribing practices were not associated with any measured reduction in hospital length of stay or infection-related readmission or death within 30 days. Whether the use of BLAST can improve these outcomes for patients with reported β-lactam allergy remains highly plausible given the known adverse outcomes associated with these reported allergies [1] [2] [3] [4] [5] [6] , but our study was simply underpowered to detect this difference.
We also identified challenges in offering BLAST to all eligible patients. Similar to other evaluations of inpatient BLAST [19] , the most common reason for exclusion was the patient being discharged within 24 hours of the clinical assessment. The BLAST procedure itself is also labor intensive as it requires nearly 1 hour at the bedside and clinical reassessment after the β-lactam challenge before switching to preferred therapy. For this reason, we deliberately reserved BLAST for patients who would be most likely to benefit. Prior studies have evaluated the use of proactive BLAST for all hospitalized patients with reported β-lactam allergy [20, 21] or patients with infectious diseases who report β-lactam allergy [19] , while we limited the use of BLAST to patients with infectious diseases where β-lactam therapy was the preferred treatment but could not be administered safely due to the severity of the reported β-lactam allergy. Utilizing BLAST at the point of care when it can alter patient management may be more feasible for ASPs that have limited resources due to other competing stewardship interventions. Our study has several important limitations. First, the number of patients who underwent BLAST in our multicenter evaluation was relatively small and not powered to detect improvement in clinical outcomes and overall safety of this intervention. As our study was primarily designed to evaluate the feasibility of performing point-of-care BLAST by ASPs, the specific testing protocol should be adapted to other institutions in consultation with allergy specialists. Second, receipt of preferred β-lactam therapy as our primary outcome was defined based on the ID physician's recommendation and not standardized between hospitals. However, each hospital's own definition of preferred β-lactam therapy remained consistent throughout the study, and independently observed improvement was noted at each hospital site compared to baseline. Finally, changes in prescribing practices could have been related to confounding variables, but we performed multivariate analysis to adjust for receipt of preferred β-lactam therapy.
Our study demonstrates the feasibility of performing BLAST as an antimicrobial stewardship activity to safely promote the use of preferred β-lactam therapy, especially when the history is not sufficient to exclude a severe IgE-mediated reaction. Longer-term studies are needed to better assess the safety and clinical impact of this ASP intervention.
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